ArticleDiscover oncology2025
Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design.
Xiaoyan Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it